Study of TNF-Antagonism in the Metabolic Syndrome (II)

Completed 40 enrolled Massachusetts General Hospital Amgen · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.

Timeline

Start: 2006-12
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous

Study of TNF-Antagonism in the Metabolic Syndrome (II)

Summary

Timeline

Drugs

Indications